Guararapes Confecções S.A. (BVMF:GUAR3)
Brazil · Delayed Price · Currency is BRL 7.67
-0.06 (-0.78%)
Aug 1, 2025, 5:06 PM GMT-3
Verve Therapeutics Income Statement
Financials in millions BRL. Fiscal year is January - December.
Millions BRL. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
| 9,846 | 9,634 | 8,795 | 8,459 | 7,221 | 6,245 | Upgrade | |
Revenue Growth (YoY) | 9.86% | 9.54% | 3.98% | 17.14% | 15.63% | -20.01% | Upgrade |
Cost of Revenue | 4,013 | 3,970 | 3,685 | 3,538 | 3,333 | 3,085 | Upgrade |
Gross Profit | 5,832 | 5,665 | 5,111 | 4,921 | 3,888 | 3,161 | Upgrade |
Selling, General & Admin | 4,898 | 4,792 | 4,702 | 4,652 | 3,683 | 3,351 | Upgrade |
Other Operating Expenses | 125.48 | 94.27 | 35.29 | -93.51 | -206.67 | -158.6 | Upgrade |
Operating Expenses | 5,041 | 4,904 | 4,738 | 4,559 | 3,476 | 3,192 | Upgrade |
Operating Income | 791.09 | 760.38 | 373.08 | 362.54 | 411.57 | -31.42 | Upgrade |
Interest Expense | -428.46 | -472.83 | -668.06 | - | -358.86 | -279.36 | Upgrade |
Interest & Investment Income | 132.8 | 157.84 | 236.1 | 253.88 | 158.42 | 110.2 | Upgrade |
Currency Exchange Gain (Loss) | -23.15 | -48.63 | -0.74 | - | - | - | Upgrade |
Other Non Operating Income (Expenses) | 3.16 | -36.27 | -16.55 | -660.58 | - | - | Upgrade |
EBT Excluding Unusual Items | 475.44 | 360.49 | -76.17 | -44.15 | 211.13 | -200.58 | Upgrade |
Gain (Loss) on Sale of Assets | 1.45 | 1.45 | 54.96 | - | - | - | Upgrade |
Pretax Income | 476.89 | 361.95 | -21.21 | -44.15 | 211.13 | -200.58 | Upgrade |
Income Tax Expense | 151.41 | 126.81 | 13.05 | -96.13 | -242 | -173.43 | Upgrade |
Net Income | 325.48 | 235.14 | -34.26 | 51.98 | 453.13 | -27.15 | Upgrade |
Net Income to Common | 325.48 | 235.14 | -34.26 | 51.98 | 453.13 | -27.15 | Upgrade |
Net Income Growth | 1233.23% | - | - | -88.53% | - | - | Upgrade |
Shares Outstanding (Basic) | 499 | 499 | 499 | 499 | 499 | 499 | Upgrade |
Shares Outstanding (Diluted) | 499 | 499 | 499 | 499 | 499 | 499 | Upgrade |
Shares Change (YoY) | -0.00% | - | 0.00% | -0.00% | 0.01% | -0.01% | Upgrade |
EPS (Basic) | 0.65 | 0.47 | -0.07 | 0.10 | 0.91 | -0.05 | Upgrade |
EPS (Diluted) | 0.65 | 0.47 | -0.07 | 0.10 | 0.91 | -0.05 | Upgrade |
EPS Growth | 1233.30% | - | - | -88.53% | - | - | Upgrade |
Free Cash Flow | 848.54 | 1,340 | 1,194 | 832.49 | -203.94 | 1,275 | Upgrade |
Free Cash Flow Per Share | 1.70 | 2.69 | 2.39 | 1.67 | -0.41 | 2.56 | Upgrade |
Dividend Per Share | - | - | 0.120 | 0.141 | 0.470 | 0.406 | Upgrade |
Dividend Growth | - | - | -14.45% | -70.11% | 15.82% | -51.69% | Upgrade |
Gross Margin | 59.24% | 58.80% | 58.11% | 58.18% | 53.84% | 50.61% | Upgrade |
Operating Margin | 8.04% | 7.89% | 4.24% | 4.29% | 5.70% | -0.50% | Upgrade |
Profit Margin | 3.31% | 2.44% | -0.39% | 0.61% | 6.28% | -0.43% | Upgrade |
Free Cash Flow Margin | 8.62% | 13.91% | 13.57% | 9.84% | -2.82% | 20.42% | Upgrade |
EBITDA | 940.49 | 972.04 | 608.04 | 743.92 | 743.33 | 285.84 | Upgrade |
EBITDA Margin | 9.55% | 10.09% | 6.91% | 8.79% | 10.29% | 4.58% | Upgrade |
D&A For EBITDA | 149.4 | 211.66 | 234.96 | 381.38 | 331.76 | 317.26 | Upgrade |
EBIT | 791.09 | 760.38 | 373.08 | 362.54 | 411.57 | -31.42 | Upgrade |
EBIT Margin | 8.04% | 7.89% | 4.24% | 4.29% | 5.70% | -0.50% | Upgrade |
Effective Tax Rate | 31.75% | 35.03% | - | - | - | - | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.